An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours
2018 ◽
Vol 103
◽
pp. 17-23
◽
H.-T. Arkenau
◽
A. Italiano
◽
G. Mak
◽
M. Toulmonde
◽
R.D. Baird
◽
...
2006 ◽
Vol 79
(2)
◽
pp. P10-P10
◽
F GUO
◽
S LETRENT
◽
D NOE
◽
A QIN
◽
K ROHRBACHER
◽
...
2009 ◽
Vol 108
(2)
◽
pp. 492-500
◽
Bo Feng
◽
Jinghai J. Xu
◽
Yi-An Bi
◽
Rouchelle Mireles
◽
Ralph Davidson
◽
...
2009 ◽
Vol 4
(6)
◽
pp. e5933
◽
Hwang-Phill Kim
◽
Young-Kwang Yoon
◽
Jin-Won Kim
◽
Sae-Won Han
◽
Hyung-Seok Hur
◽
...
2008 ◽
Vol 26
(15_suppl)
◽
pp. 14688-14688
Z. A. Wainberg
◽
J. Dering
◽
C. Ginther
◽
A. Anghel
◽
O. Kalous
◽
...
1999 ◽
Vol 99
(25)
◽
pp. 3292-3299
◽
Glenda Bilder
◽
Tara Wentz
◽
Robert Leadley
◽
Dilip Amin
◽
Lisa Byan
◽
...
2015 ◽
Vol 14
(1)
◽
pp. 18-24.e1
◽
Corina N. Oldenhuis
◽
Walter J. Loos
◽
Brooke Esteves
◽
Leni van Doorn
◽
Monette M. Cotreau
◽
...
2001 ◽
Vol 33
(7)
◽
pp. 451-455
◽
Heikki Joensuu
◽
Sasa Dimitrijevic
2019 ◽
Vol 18
(13)
◽
pp. 1513-1522
◽
Jiayao Li
◽
Qian Xiao
◽
Yi Bao
◽
Wenyu Wang
◽
Jianyuan Goh
◽
...
Ingrid A. Mayer
◽
Barbara B. Haley
◽
Vandana G. Abramson
◽
Adam Brufsky
◽
Brent Rexer
◽
...
2007 ◽
Vol 4
(1)
◽
pp. 14
◽
Peter Hinow
◽
Shizhen Wang
◽
Carlos L Arteaga
◽
Glenn F Webb